40 related articles for article (PubMed ID: 19528482)
1. Overexpression of human osteopontin increases cell proliferation and migration in human embryo kidney-293 cells.
Liu YJ; Zhang DQ; Sui XM; Tian W
Cell Mol Biol Lett; 2009; 14(4):670-8. PubMed ID: 19562270
[TBL] [Abstract][Full Text] [Related]
2. Immunoregulatory Roles of Osteopontin in Diseases.
Wang L; Niu X
Nutrients; 2024 Jan; 16(2):. PubMed ID: 38276550
[TBL] [Abstract][Full Text] [Related]
3. Osteopontin, GLUT1 and Ki-67 expression in malignant peritoneal mesothelioma: prognostic implications.
Liu Y; Zheng G; Yang D; Guo X; Tian L; Song H; Liang Y
Intern Med J; 2021 Jun; 51(6):896-904. PubMed ID: 32510678
[TBL] [Abstract][Full Text] [Related]
4. Biomarkers for Early Diagnosis and Prognosis of Malignant Pleural Mesothelioma: The Quest Goes on.
Ledda C; Senia P; Rapisarda V
Cancers (Basel); 2018 Jun; 10(6):. PubMed ID: 29914087
[TBL] [Abstract][Full Text] [Related]
5. Serum mesothelin and other biomarkers: what have we learned in the last decade?
Cristaudo A; Bonotti A; Guglielmi G; Fallahi P; Foddis R
J Thorac Dis; 2018 Jan; 10(Suppl 2):S353-S359. PubMed ID: 29507805
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic and prognostic biomarkers for malignant mesothelioma: an update.
Chen Z; Gaudino G; Pass HI; Carbone M; Yang H
Transl Lung Cancer Res; 2017 Jun; 6(3):259-269. PubMed ID: 28713671
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of several biomarkers for the patients with malignant pleural mesothelioma.
Liu H; Wu L; Ji K; Wang W
Tumour Biol; 2015 Sep; 36(10):7375-84. PubMed ID: 26361957
[TBL] [Abstract][Full Text] [Related]
8. NF2 blocks Snail-mediated p53 suppression in mesothelioma.
Cho JH; Lee SJ; Oh AY; Yoon MH; Woo TG; Park BJ
Oncotarget; 2015 Apr; 6(12):10073-85. PubMed ID: 25823924
[TBL] [Abstract][Full Text] [Related]
9. Asbestos-induced cellular and molecular alteration of immunocompetent cells and their relationship with chronic inflammation and carcinogenesis.
Matsuzaki H; Maeda M; Lee S; Nishimura Y; Kumagai-Takei N; Hayashi H; Yamamoto S; Hatayama T; Kojima Y; Tabata R; Kishimoto T; Hiratsuka J; Otsuki T
J Biomed Biotechnol; 2012; 2012():492608. PubMed ID: 22500091
[TBL] [Abstract][Full Text] [Related]
10. Asbestos induces reduction of tumor immunity.
Kumagai-Takei N; Maeda M; Chen Y; Matsuzaki H; Lee S; Nishimura Y; Hiratsuka J; Otsuki T
Clin Dev Immunol; 2011; 2011():481439. PubMed ID: 22007251
[TBL] [Abstract][Full Text] [Related]
11. Osteopontin is linked to p65 and MMP-9 expression in pulmonary adenocarcinoma but not in malignant pleural mesothelioma.
Frey AB; Wali A; Pass H; Lonardo F
Histopathology; 2007 May; 50(6):720-6. PubMed ID: 17493236
[TBL] [Abstract][Full Text] [Related]
12. alpha7-Nicotinic receptor antagonists at the beginning of a clinical era for NSCLC and Mesothelioma?
Paleari L; Cesario A; Fini M; Russo P
Drug Discov Today; 2009 Sep; 14(17-18):822-36. PubMed ID: 19616116
[TBL] [Abstract][Full Text] [Related]
13. Osteopontin and the skin: multiple emerging roles in cutaneous biology and pathology.
Buback F; Renkl AC; Schulz G; Weiss JM
Exp Dermatol; 2009 Sep; 18(9):750-9. PubMed ID: 19558497
[TBL] [Abstract][Full Text] [Related]
14. Osteopontin modulates malignant pleural mesothelioma cell functions in vitro.
Ohashi R; Tajima K; Takahashi F; Cui R; Gu T; Shimizu K; Nishio K; Fukuoka K; Nakano T; Takahashi K
Anticancer Res; 2009 Jun; 29(6):2205-14. PubMed ID: 19528482
[TBL] [Abstract][Full Text] [Related]
15. Osteopontin-mediated enhanced hyaluronan binding induces multidrug resistance in mesothelioma cells.
Tajima K; Ohashi R; Sekido Y; Hida T; Nara T; Hashimoto M; Iwakami S; Minakata K; Yae T; Takahashi F; Saya H; Takahashi K
Oncogene; 2010 Apr; 29(13):1941-51. PubMed ID: 20101228
[TBL] [Abstract][Full Text] [Related]
16. Osteopontin increases migration and MMP-9 up-regulation via alphavbeta3 integrin, FAK, ERK, and NF-kappaB-dependent pathway in human chondrosarcoma cells.
Chen YJ; Wei YY; Chen HT; Fong YC; Hsu CJ; Tsai CH; Hsu HC; Liu SH; Tang CH
J Cell Physiol; 2009 Oct; 221(1):98-108. PubMed ID: 19475568
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
